PI Global Investments
Precious Metals

Asahi Kasei: Closed-Loop Recycling for Iridium and Ruthenium


Asahi Kasei key strategic partners

Teijin: Asahi Kasei and Teijin merged their respective trading subsidiaries, Asahi Kasei Advance and Teijin Frontier, into a single joint venture operating under Teijin Frontier, owned 80% by Teijin and 20% by Asahi Kasei. Rather than pursuing standalone growth, the integration combines both companies’ global procurement capabilities, manufacturing strengths, and sales networks across fibers, textiles, chemicals, and industrial materials. Ahead of the merger, Asahi Kasei also transferred its Chinese textile subsidiary, Hangzhou Asahikasei Textiles, into the combined entity to create a more competitive, unified commercial platform.

Honda: Asahi Kasei and Honda Motor Co. signed a shareholders’ agreement to convert Asahi Kasei’s Canadian subsidiary into a joint venture, tentatively named Asahi Kasei Honda Battery Separator Corporation, to produce lithium-ion battery separators in North America. Under the deal, Honda Canada will invest approximately C$417 million (US$300 million) to acquire a 25% stake in the entity, combining Asahi Kasei’s Hipore material technology with Honda’s electrification capabilities to secure a localised EV battery supply chain.

AGC Biologics: Asahi Kasei Pharma entered into a manufacturing agreement with contract development and manufacturing organisation AGC Biologics to produce clinical drug substances for its antibody-based therapies at AGC’s Seattle facility. Under the partnership, AGC Biologics is handling process transfer, optimisation, analytical development, and regulatory documentation to prepare Asahi Kasei’s monoclonal antibody candidates for late-stage clinical development and commercialisation.



Source link

Related posts

First female Archbishop of Canterbury to meet Pope Leo – The Herald Palladium

D.William

Bless Collection Hotels Opens First Barcelona Hotel in 2026

D.William

Chris Boshoff: FDA Approves First Platinum-Free Perioperative Regimen for Muscle-Invasive Bladder Cancer

D.William

Leave a Comment